Bristol-Myers Squibb Company (BMY) key performance indicators and operating metrics (47 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total company revenues | 11.5B | FY2026-Q1 |
| Growth Portfolio revenues | 6.2B | FY2026-Q1 |
| International revenues | 3.7B | FY2026-Q1 |
| Total Revenues, net | 11.5B | FY2026-Q1 |
| U.S. revenues | 7.8B | FY2026-Q1 |
| Legacy Portfolio revenues | 5.3B | FY2026-Q1 |
| Growth portfolio revenue growth (reported, YoY) | 12.00 percent | FY2026-Q1 |
| Earnings per share (non-GAAP, quarterly) | 1.58 USD_per_share | FY2026-Q1 |
| Quarterly tax rate (YoY change; current rate) | 17.30 percent | FY2026-Q1 |
| Gross margin (non-GAAP key metric as discussed) | 70.30 percent | FY2026-Q1 |
| Total Cash | 10.9B | FY2026-Q1 |
| Total Debt | 44.5B | FY2026-Q1 |
| Acquired In-Process Research and Development (Acquired IPR&D) charge | 100M | FY2026-Q1 |
| Operating Expenses | 4.3B | FY2026-Q1 |
Back to BMY overview · BMY earnings · BMY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.